iBio’s IBIO-610 Shows Muscle-Preserving Potential in Obese Primate Study
Event summary
- iBio’s IBIO-610, an Activin E antibody, combined with semaglutide, resulted in 93% fat loss vs. 77% with semaglutide alone in an 8-week obese non-human primate study.
- IBIO-610 demonstrated a 97% reduction in serum levels of active Activin E and a 33.2-day half-life in NHPs, with a projected human half-life potentially supporting twice-yearly dosing.
- iBio plans to initiate first-in-human trials of IBIO-610 in the first half of 2027.
The big picture
iBio’s data suggests a potential breakthrough in obesity treatment by preserving muscle mass during weight loss, a critical unmet need in the GLP-1 therapy space. The company’s focus on long-acting antibody therapeutics aligns with the industry’s shift towards more sustainable and effective obesity management solutions. Success in human trials could position iBio as a key player in the cardiometabolic disease market.
What we're watching
- Clinical Translation
- Whether the muscle-preserving effects observed in NHPs will translate to human trials starting in 2027.
- Regulatory Pathway
- The pace at which iBio can navigate regulatory approvals for IBIO-610 as a combination therapy.
- Market Differentiation
- How IBIO-610’s potential twice-yearly dosing could position it against existing GLP-1 therapies.
Related topics